Timing Pegfilgrastim Dose in Breast Cancer Patients
Part of Cancer, Skin clinical trials.
This study looks at whether changing the timing of pegfilgrastim (a medicine used to help prevent low white blood cell counts during chemotherapy) affects outcomes in people with primary breast cancer. It may help your care team choose the best dosing schedule for you during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70
- You have confirmed primary breast cancer (from a lab test of tissue or cells)
- You can receive your chemotherapy exactly as planned in the study
- You can read and understand Chinese and complete questionnaires on your own
- You can sign consent to join the study
- You do not regularly take prescription or over-the-counter medicines for ongoing chronic pain
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
Hear when a new Bone Pain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.